CD68 and non-small cell lung carcinoma: Overall, these findings highlight the importance of considering the heterogeneity of TAMs in NSCLC and suggest that targeting specific TAM subpopulations, such as CD68+SHP2+ TAMs, may offer new opportunities for improving patient outcomes in NSCLC.